A composition for proliferating animal Bifidobacterium lactis subspecies and its application

Abstract

The invention discloses a composition and application thereof for proliferating animal bifidobacterium lactis subspecies, belonging to the field of probiotics, including a prebiotic composition and a Chinese medicine composition; wherein the mass ratio of the prebiotic composition and the Chinese medicine composition is 5~10:1~5; the prebiotic composition includes at least three of oligomannosaccharides, cottonseed oligosaccharides, isomaltooligosaccharides and oligogalactoses; the Chinese medicine composition includes Chinese medicine and ginseng powder, wherein the Chinese medicine includes at least two of astragalus, licorice, ginger, and cinnamon. The present invention screens out a composition that can efficiently proliferate animal bifidobacterium lactis subspecies, taking into account the proliferation speed and proliferation amount, and enhancing the probiotic effect of probiotics. The composition can help animal bifidobacterium lactis subspecies proliferate, has the advantages of both rapid and high growth, and exerts more health effects.

Description

Technical Field

[0001] The invention belongs to the field of probiotics, and specifically relates to a composition for proliferating animal Bifidobacterium lactis subspecies and an application thereof. Background Art

[0002] Bifidobacterium animalis subsp. lactis Bifidobacterium animalis subsp. lactis ) is one of the most widely used probiotic species, which has the effects of regulating intestinal microbial flora, improving intestinal function, reducing diarrhea, inhibiting pathogens, enhancing intestinal barrier, regulating host immunity, etc. These effects involve adhesion and colonization, antibacterial production, nutritional competition, production of short-chain fatty acids, and communication with the immune system. Obviously, these mechanisms require a sufficient number and activity of probiotics. It is worth noting that animal Bifidobacterium is not an indigenous strain in the human intestinal flora. As an oral probiotic of foreign strains, its probiotic effect in the colon is limited by competition from the indigenous intestinal flora. Developing prebiotics that are synergistically compounded with animal Bifidobacterium lactis subspecies for efficient proliferation can help the target probiotics gain a nutritional competitive advantage over the indigenous flora in the colon, which is more conducive to their health effects.

[0003] In addition to the commonly used prebiotics that can proliferate bifidobacteria, traditional Chinese medicine ingredients also show positive interactions with probiotics, but the current understanding of the mechanism of their interaction is not systematic and comprehensive. At this stage, researchers believe that the interaction mechanism between probiotics and traditional Chinese medicine mainly involves that probiotics can transform the ingredients in traditional Chinese medicine into a more bioavailable form through biotransformation, such as the metabolism of ginsenosides; on the other hand, Chinese medicine ingredients can also selectively promote the growth of intestinal probiotics, for example: Rehmannia polysaccharides can significantly promote the proliferation of bifidobacteria and lactobacilli in the intestines of diabetic rats; eating yam significantly improved the composition of the intestinal flora of mice, among which the abundance of lactobacilli and bifidobacteria increased, and the number of Clostridium perfringens decreased; low concentrations of honeysuckle extract can maintain the microbial homeostasis in the rat intestine, significantly promote the growth of lactobacilli and bifidobacteria, and at the same time reduce the number of Escherichia coli.

[0004] Based on the above background, the combination of suitable Chinese herbal ingredients and prebiotics may help probiotics such as animal bifidobacterium lactis subspecies to proliferate and exert more health effects. However, the combination of prebiotics and Chinese herbal ingredients, as well as the synergistic proliferation effect of their complexes on probiotics have not been fully studied. For example, CN117751982A discloses a nutritional composition and its application for promoting the colonization of bifidobacteria. The prebiotic combination of the invention is mainly screened from the prebiotic spectrum: polydextrose, galacto-oligosaccharide, and oligofructose. It is not evaluated from the perspective of rapid and high value-added, and the advantages of rapid proliferation of Chinese herbal ingredients are not played; CN117925444A discloses a Chinese herbal medicine composition and its application for promoting the growth of probiotics. The prebiotic combination of the invention is mainly screened from the prebiotic spectrum: inulin, oligofructose, and oligoxylose. It does not cover more matching prebiotic ingredients, does not compare the differences between prebiotics and Chinese herbal extracts in the proliferation of probiotics, and does not reflect the logic of rapid and high value-added design of the composition. Summary of the invention

[0005] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.

[0006] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.

[0007] Therefore, the object of the present invention is to overcome the deficiencies in the prior art and provide a composition for proliferating animal Bifidobacterium lactis subsp.

[0008] In order to solve the above technical problems, the present invention provides the following technical solutions: a composition for proliferating animal Bifidobacterium lactis subspecies, comprising a prebiotic composition and a traditional Chinese medicine composition;

[0009] Wherein, the mass ratio of the prebiotic composition to the traditional Chinese medicine composition is 5-10: 1-5, preferably, the mass ratio of the prebiotic composition to the traditional Chinese medicine composition is 7-10: 1-3;

[0010] The prebiotic composition comprises at least three of manno-oligosaccharides, raffinose oligosaccharides, isomaltooligosaccharides and galacto-oligosaccharides;

[0011] The Chinese medicine composition comprises Chinese medicine and ginseng powder, wherein the Chinese medicine comprises at least two of astragalus, liquorice, ginger, and cinnamon.

[0012] As a preferred embodiment of the prebiotic Chinese medicine composition of the present invention, the mass ratio of the Chinese medicine to the ginseng powder is 80-120:1, preferably, the mass ratio of the Chinese medicine to the ginseng powder is 90-100:1.

[0013] As a preferred embodiment of the prebiotic Chinese medicine composition of the present invention, the total ginsenosides in the ginseng powder are ≥5%.

[0014] As a preferred embodiment of the prebiotic Chinese medicine composition of the present invention, the Chinese medicine comprises astragalus, licorice and cinnamon, and the mass ratio of astragalus, licorice and cinnamon is 5-10:1-2.5:1; or

[0015] The Chinese medicine comprises astragalus, ginger and cinnamon, and the mass ratio of the astragalus, ginger and cinnamon is 5-10: 1-2: 1; or

[0016] The Chinese medicine comprises liquorice, ginger and cinnamon, and the mass ratio of the liquorice, ginger and cinnamon is 1-2.5: 1-2: 1; or

[0017] The Chinese medicine comprises astragalus, licorice, cinnamon, ginger and cinnamon, and the mass ratio of astragalus, licorice, ginger and cinnamon is 5~10:1~2.5:1~2:1.

[0018] As a preferred embodiment of the prebiotic Chinese medicine composition of the present invention, the prebiotic composition comprises mannooligosaccharides, raffinose oligosaccharides and isomaltooligosaccharides, wherein, in parts by weight, the mannooligosaccharides are 0.01-50 parts, the raffinose oligosaccharides are 0.01-50 parts, and the isomaltooligosaccharides are 0.01-50 parts. Preferably, the mannooligosaccharides are 16.7-50 parts, the raffinose oligosaccharides are 16.7-50 parts, and the isomaltooligosaccharides are 16.7-50 parts; or

[0019] The prebiotic composition comprises mannooligosaccharide, raffinose oligosaccharide and galactooligosaccharide, wherein, by weight, the mannooligosaccharide is 0.01-50 parts, the raffinose oligosaccharide is 0.01-50 parts, and the galactooligosaccharide is 0.01-50 parts, preferably, the mannooligosaccharide is 16.7-50 parts, the raffinose oligosaccharide is 16.7-50 parts, and the galactooligosaccharide is 16.7-50 parts; or

[0020] The prebiotic composition comprises cottonseed oligosaccharide, isomaltooligosaccharide and galacto-oligosaccharide, wherein, by weight, the cottonseed oligosaccharide is 0.01-50 parts, the isomaltooligosaccharide is 0.01-50 parts, and the galacto-oligosaccharide is 0.01-50 parts, preferably, the cottonseed oligosaccharide is 16.7-50 parts, the isomaltooligosaccharide is 16.7-50 parts, and the galacto-oligosaccharide is 16.7-50 parts; or

[0021] The prebiotic composition comprises mannooligosaccharides, raffinose oligosaccharides, isomaltooligosaccharides and galacto-oligosaccharides. In parts by weight, the mannooligosaccharides are 0.01-50 parts, the raffinose oligosaccharides are 0.01-50 parts, the isomaltooligosaccharides are 0.01-50 parts, and the galacto-oligosaccharides are 0.01-50 parts. Preferably, the mannooligosaccharides are 16.7-50 parts, the raffinose oligosaccharides are 16.7-50 parts, the isomaltooligosaccharides are 16.7-50 parts, and the galacto-oligosaccharides are 16.7-50 parts.

[0022] Another object of the present invention is to overcome the deficiencies in the prior art and provide a composition containing animal Bifidobacterium lactis subsp. for use in preparing food, health food and medicine for proliferating animal Bifidobacterium lactis subsp.

[0023] As a preferred embodiment of the application of the present invention, the dosage forms of the food, health food and medicine include soft candy, beverage, powder, tablet, hard capsule and soft capsule.

[0024] Another object of the present invention is to overcome the deficiencies in the prior art and provide a composition containing animal Bifidobacterium lactis subspecies, comprising a composition and animal Bifidobacterium lactis subspecies, wherein the number of viable bacteria of animal Bifidobacterium lactis subspecies added per gram of prebiotic composition is 10 6 -10 12 indivual.

[0025] Another object of the present invention is to overcome the deficiencies in the prior art and provide a composition containing animal Bifidobacterium lactis subsp. for use in preparing food, health food and medicine for proliferating animal Bifidobacterium lactis subsp.

[0026] As a preferred embodiment of the application of the present invention, the dosage forms of the food, health food and medicine include soft candy, beverage, powder, tablet, hard capsule and soft capsule.

[0027] Beneficial effects of the present invention:

[0028] The present invention screens out a composition that can efficiently proliferate animal Bifidobacterium lactis subsp., takes into account both the proliferation speed and the proliferation amount, and enhances the probiotic effect of probiotics. The composition can help animal Bifidobacterium lactis subsp. proliferate, has the advantages of rapid and high growth, and exerts more health effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0030] Figure 1 The absorbance value (OD value) of the cultured animal Bifidobacterium lactis subsp. lactis strain BB-12 in Example 1 of the present invention changes into a growth curve.

[0031] Figure 2 The absorbance value (OD value) of the cultured animal Bifidobacterium lactis subsp. lactis strain BB-12 in Example 2 of the present invention changes into a growth curve.

[0032] Figure 3 The absorbance value (OD value) of the cultured animal Bifidobacterium lactis subsp. lactis strain BB-12 in Example 3 of the present invention changes into a growth curve.

[0033] Figure 4 The absorbance value (OD value) of the cultured animal Bifidobacterium lactis subsp. lactis strain BB-12 in Example 3 of the present invention changes into a growth curve. DETAILED DESCRIPTION

[0034] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.

[0035] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0036] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.

[0037] The ginseng powder in the embodiment of the present invention is obtained by crushing the ginseng raw material, extracting or not extracting, fermenting or enzymolysis, filtering, powdering, and sieving, and contains ≥5% total ginsenosides, which is a common commercial product; isomaltooligosaccharide (Baolingbao), xylooligosaccharide (Henan Yichangqing), fructooligosaccharide (Baolingbao), inulin (BENEO), galacto-oligosaccharide (Quantum High-tech), resistant dextrin (Baolingbao), polydextrose (Baolingbao), cottonseed oligosaccharide (Baolingbao), and manno-oligosaccharide (Shandong Zhengsheng) are all common commercial products.

[0038] Example 1

[0039] Screening of Chinese medicinal ingredients for efficient proliferation of animal Bifidobacterium lactis subsp.

[0040] (1) Culture system: MRS carbon-free medium (10 g / L peptone, 8 g / L beef extract, 4 g / L yeast extract, 2 g / L potassium dihydrogen phosphate, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 0.2 g / L magnesium sulfate, 0.2 g / L manganese sulfate and 0.1% Tween 80) v / v ) + prebiotics or Chinese medicine composition (0.5%, w / v ), 200 μL volume was placed in a 96-well transparent flat-bottom ELISA plate, and 3 replicates were made for each condition.

[0041] (2) Chinese medicine composition to be tested:

[0042] Chinese prescription A: Mix 10 g of Astragalus, 2.5 g of Licorice, 1 g of Cinnamon, and 2 g of Ginger, add 10 times of water (mass ratio), reflux extraction twice, 1 hour each time, combine the filtrates, concentrate, dry, crush, and sieve;

[0043] Chinese prescription B: Take 5 g of ginseng, 10 g of astragalus, 2.5 g of licorice, 1 g of cinnamon, and 2 g of ginger, add 10 times water (mass ratio), reflux extraction twice, each time for 1 hour, combine the filtrate, concentrate, dry, crush, and sieve.

[0044] Chinese medicine C: Mix Chinese medicine A with ginseng powder at a ratio of 100:1 (mass ratio);

[0045] Prebiotic composition: a mixture of 33.3 g of manno-oligosaccharide, 33.3 g of cottonseed oligosaccharide, 16.7 g of isomaltooligosaccharide and 16.7 g of galacto-oligosaccharide.

[0046] (3) Culture conditions: Obtain a monoclonal colony of Bifidobacterium animalis subsp. lactis strain BB-12 (purchased from Novonesis) by streaking on an agar plate, and inoculate the single colony into fresh MRS liquid medium (containing 2% glucose) as a seed culture (37°C, anaerobic). After the seed culture reaches the mid-logarithmic phase (approximately 24-32 hours), inoculate 0.5% of the inoculum into a culture medium containing prebiotics or traditional Chinese medicine ingredients as the sole carbon source for culture (37°C, anaerobic).

[0047] (4) Detection indicators: Use a Tecan high-throughput growth curve tester to measure the absorbance (OD) value at a wavelength of 600 nm from 0 to 36 h. Set a 9-point detection matrix in a square in each well, and take the average value as the OD reading of the well. The final result is the average value of 3 replicate wells.

[0048] The OD value changes of Bifidobacterium animalis subsp. lactis strain BB-12 were plotted as a growth curve. Figure 1 .

[0049] Compared with commonly used prebiotics, Chinese herbal extracts generally shortened the lag period of bifidobacterium proliferation. Among them, the most obvious rapid proliferation effect was Kampo C, a combination of astragalus, licorice, cinnamon, ginger, and ginseng powder. That is, the Chinese herbal composition containing astragalus, licorice, cinnamon, ginger, and ginseng powder can significantly shorten the lag period of Bifidobacterium lactis proliferation.

[0050] The Chinese herbal medicine ingredients have the advantage of rapidly proliferating animal Bifidobacterium lactis subspecies and reducing the lag period of proliferation of animal Bifidobacterium lactis subspecies, and the proliferation amount is less than that of commonly used prebiotics such as isomaltooligosaccharide and galacto-oligosaccharide.

[0051] Therefore, it is considered to combine traditional Chinese medicine ingredients with prebiotic compositions to achieve both rapid and high biomass proliferation effects.

[0052] Example 2

[0053] Screening for a composition that allows for rapid and high biomass proliferation of animal Bifidobacterium lactis subsp.

[0054] (1) Culture system: MRS carbon-free medium (10 g / L peptone, 8 g / L beef extract, 4 g / L yeast extract, 2 g / L potassium dihydrogen phosphate, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 0.2 g / L magnesium sulfate, 0.2 g / L manganese sulfate and 0.1% Tween 80) v / v )+ Chinese medicine-prebiotics combination (0.5%, w / v ), 200 μL volume was placed in a 96-well transparent flat-bottom ELISA plate, and three replicates were made for each condition.

[0055] (2) Chinese medicine to be tried:

[0056] Chinese prescription A: Mix 10 g of Astragalus, 2.5 g of Licorice, 1 g of Cinnamon, and 2 g of Ginger, add 10 times of water (mass ratio), reflux extraction twice, 1 hour each time, combine the filtrates, concentrate, dry, crush, and sieve;

[0057] Chinese medicine C: Mix Chinese medicine A with ginseng powder at a ratio of 100:1 (mass ratio);

[0058] (3) Chinese medicine-prebiotic combination to be tested:

[0059] The experiment was carried out according to the scheme in Table 1 to compare the proliferation effects of different compositions on Bifidobacterium animalis subsp. lactis.

[0060] Combination principle: the total amount of Chinese herbal ingredients and prebiotics remains unchanged, and the ratio between the two is adjusted.

[0061] Table 1 Screening scheme for the ratio of Chinese herbal medicine C and prebiotics

[0062]

[0063] (4) Culture conditions: Obtain a monoclonal colony of Bifidobacterium animalis subsp. lactis strain BB-12 (purchased from Novonesis) by streaking on an agar plate, and inoculate the single colony into fresh MRS liquid medium (containing 2% glucose) as a seed culture medium (37°C, anaerobic). After the seed culture medium is cultured to the mid-logarithmic phase (approximately 24-32 hours), inoculate 0.5% of the inoculum into a culture medium containing prebiotics and / or traditional Chinese medicine as a carbon source for culture (37°C, anaerobic).

[0064] (5) Detection index: Using Tecan high-throughput growth curve tester, the absorbance (OD) value was measured at a wavelength of 600 nm from 0 to 24 h, with a detection interval of 30 minutes. A 9-point detection matrix was set in each well in a square shape, and the average value was taken as the OD reading. The final result was the average value of 3 replicate wells. Animal Bifidobacterium lactis subsp. lactis strain BB-12 was cultured with different compositions as the sole carbon source, and the changes in its OD value were plotted as a growth curve ( Figure 2 )

[0065] Figure 2 The results showed that the prebiotic Chinese medicine composition containing Kampo C had a proliferation effect on Bifidobacterium lactis subsp. animalis. The prebiotic composition containing 10%-30% Kampo C shortened the lag period while taking into account a higher proliferation amount. The formula promoted the proliferation of Bifidobacterium lactis subsp. animalis in the intestine in a way that took into account both rapid proliferation and high proliferation amount. The proliferation effect of the Chinese medicine prebiotic composition and common prebiotics on Bifidobacterium lactis subsp. animalis showed all-round advantages in proliferation speed and proliferation amount.

[0066] Example 3

[0067] Effects of different contents of traditional Chinese medicine-prebiotic compositions on the proliferation of Bifidobacterium animalis subsp. lactis.

[0068] (1) Culture system: MRS carbon-free medium (10 g / L peptone, 8 g / L beef extract, 4 g / L yeast extract, 2 g / L potassium dihydrogen phosphate, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 0.2 g / L magnesium sulfate, 0.2 g / L manganese sulfate and 0.1% Tween 80) v / v )+ Chinese medicine-prebiotics combination (0.5%, w / v ), 200 μL volume was placed in a 96-well transparent flat-bottom ELISA plate, and three replicates were made for each condition.

[0069] (2) Chinese medicine composition to be tested:

[0070] Chinese prescription A: Mix 10 g of Astragalus, 2.5 g of Licorice, 1 g of Cinnamon, and 2 g of Ginger, add 10 times of water (mass ratio), reflux extraction twice, 1 hour each time, combine the filtrates, concentrate, dry, crush, and sieve;

[0071] Chinese medicine C: Mix Chinese medicine A with ginseng powder at a ratio of 100:1 (mass ratio);

[0072] Chinese prescription D: Mix 2.5 g of licorice, 1 g of cinnamon, and 2 g of ginger, add 10 times of water (mass ratio), reflux extraction twice, each time for 1 hour, combine the filtrate, concentrate, dry, crush, and sieve;

[0073] Chinese prescription E: Mix 10 g of astragalus, 1 g of cinnamon bark, and 2 g of ginger, add 10 times water (mass ratio), reflux extraction twice, each time for 1 hour, combine the filtrate, concentrate, dry, crush, and sieve;

[0074] Chinese prescription F: Mix 10 g of Astragalus, 2.5 g of Licorice, and 1 g of Cinnamon, add 10 times water (mass ratio), reflux extraction twice, 1 hour each time, combine the filtrates, concentrate, dry, crush, and sieve;

[0075] Chinese medicine G: Mix Chinese medicine D and ginseng powder at a ratio of 100:1 (mass ratio);

[0076] Chinese medicine H: Mix Chinese medicine E and ginseng powder at a ratio of 100:1 (mass ratio);

[0077] Chinese medicine I: Mix Chinese medicine F and ginseng powder at a ratio of 100:1 (mass ratio);

[0078] (3) Chinese medicine-prebiotic combination to be tested:

[0079] The experiment was carried out according to the scheme in Table 2 to compare the proliferation effects of different Chinese medicine-prebiotic compositions on Bifidobacterium animalis subsp. lactis.

[0080] Table 2 Screening scheme for the content of Chinese medicinal ingredients in Chinese herbal medicine-prebiotic combination

[0081]

[0082] (4) Culture conditions: Obtain a monoclonal colony of Bifidobacterium animalis subsp. lactis strain BB-12 (purchased from Novonesis) by streaking on an agar plate, and inoculate the single colony into fresh MRS liquid medium (containing 2% glucose) as a seed culture medium (37°C, anaerobic). After the seed culture medium is cultured to the mid-logarithmic phase (approximately 24-32 hours), inoculate 0.5% of the inoculum into a culture medium containing prebiotics and / or traditional Chinese medicine as a carbon source for culture (37°C, anaerobic).

[0083] (5) Detection index: Using Tecan high-throughput growth curve tester, the absorbance (OD) value was measured at a wavelength of 600 nm from 0 to 24 h, with a detection interval of 30 minutes. A 9-point detection matrix was set in each well in a square shape, and the average value was taken as the OD reading. The final result was the average value of 3 replicate wells. Animal Bifidobacterium lactis subsp. lactis strain BB-12 was cultured with different compositions as the sole carbon source, and the changes in its OD value were plotted as a growth curve ( Figure 3 ,4)

[0084] Figure 3 and Figure 4 The effect of the tested Chinese medicine-prebiotic combination on the proliferation of animal Bifidobacterium lactis subspecies was demonstrated. The Chinese medicine-prebiotic combination containing 10%-30% Chinese medicine ingredients shortened the lag period while taking into account a higher proliferation amount.

[0085] The core formula with ginseng powder is used to promote the proliferation of animal Bifidobacterium lactis subspecies in the intestine in a way that takes into account both rapid proliferation and high proliferation amount. The proliferation effect of this Chinese herbal prebiotic composition and common prebiotics on animal Bifidobacterium lactis subspecies shows all-round advantages in proliferation speed and proliferation amount.

[0086] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the present invention.

Claims

1. A composition for proliferating Bifidobacterium lactis subsp. animalis, characterized in that: It consists of a prebiotic composition and a traditional Chinese medicine composition; Among them, the mass content of the Chinese medicine composition is 10%~30%; The prebiotic composition is at least three of manno-oligosaccharides, raffinose oligosaccharides, isomaltooligosaccharides and galacto-oligosaccharides; The Chinese medicine composition is composed of Chinese medicine and ginseng powder, wherein the Chinese medicine is a water extract obtained by mixing astragalus, licorice, ginger and cinnamon as raw materials, and the mass ratio of the raw materials astragalus, licorice, ginger and cinnamon is 5-10:1-2.5:1-2:1; The mass ratio of the Chinese medicine to the ginseng powder is 80-120:

1.

2. The composition according to claim 1, characterized in that: The total ginsenosides in the ginseng powder are ≥5%.

3. The composition according to claim 1, characterized in that: The prebiotic composition comprises mannooligosaccharide, raffinose oligosaccharide and isomaltooligosaccharide, wherein, by weight, the mannooligosaccharide is 0.01-50 parts, the raffinose oligosaccharide is 0.01-50 parts, and the isomaltooligosaccharide is 0.01-50 parts; or The prebiotic composition comprises mannooligosaccharide, raffinose oligosaccharide and galactooligosaccharide, wherein, by weight, the mannooligosaccharide is 0.01-50 parts, the raffinose oligosaccharide is 0.01-50 parts, and the galactooligosaccharide is 0.01-50 parts; or The prebiotic composition comprises cottonseed oligosaccharide, isomaltooligosaccharide and galacto-oligosaccharide, wherein, by weight, the cottonseed oligosaccharide is 0.01-50 parts, the isomaltooligosaccharide is 0.01-50 parts, and the galacto-oligosaccharide is 0.01-50 parts; or The prebiotic composition comprises mannooligosaccharide, raffinose oligosaccharide, isomaltooligosaccharide and galactooligosaccharide, wherein, by weight, the mannooligosaccharide is 0.01-50 parts, the raffinose oligosaccharide is 0.01-50 parts, the isomaltooligosaccharide is 0.01-50 parts and the galactooligosaccharide is 0.01-50 parts.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of health foods and medicines for the proliferation of animal Bifidobacterium lactis subsp.

5. The use according to claim 4, characterized in that: The dosage forms of the health food and medicine include soft candy, beverage, powder, tablet, hard capsule and soft capsule.

6. A composition containing Bifidobacterium animalis subsp. lactis, characterized in that: The composition comprises any one of claims 1 to 3 and Bifidobacterium lactis subsp. animalis, wherein the number of viable bacteria of Bifidobacterium lactis subsp. animalis added per gram of the prebiotic composition is 10 6 -10 12 indivual.

7. Use of the composition containing animal Bifidobacterium lactis subsp. according to claim 6 in the preparation of health food and medicine for proliferating animal Bifidobacterium lactis subsp.

8. The use according to claim 7, characterized in that: The dosage forms of the health food and medicine include soft candy, beverage, powder, tablet, hard capsule and soft capsule.

Images